FFCP PHASE1:Hg19::chr18:31431849..31431857,+: Difference between revisions
From FANTOM5_SSTAR
No edit summary |
No edit summary |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{FFCP|DPIdataset= | {{FFCP | ||
|DHSsupport=supported | |||
|DPIdataset=robust | |||
|EntrezGene=NA | |||
|GencodeV16b_All_Build2_RSEM10_CPAT_consensus=no_gencodeV16_or_build2_transcript | |||
|HGNC=NA | |||
|TSSclassifier=strong | |||
|UniProt=NA | |||
|association_with_transcript=NA | |||
|cluster_id=chr18:31431849..31431857,+ | |||
|coexpression_cluster_id=C78 | |||
|description=CAGE_peak_at_chr18:31431849..31431857,+ | |||
|id=chr18:31431849..31431857,+ | |||
|ontology_enrichment_celltype=CL:0000817!2.25e-46!3;CL:0000945!4.40e-40!24;CL:0000826!4.40e-40!24;CL:0000785!1.87e-31!2;CL:0000955!1.87e-31!2;CL:0000818!1.87e-31!2;CL:0000954!1.87e-31!2;CL:0000816!1.87e-31!2;CL:0000542!1.18e-22!53;CL:0000051!1.18e-22!53;CL:0000838!3.09e-18!52;CL:0000819!7.57e-17!1;CL:0000946!1.93e-16!1;CL:0000786!1.93e-16!1;CL:0000980!1.93e-16!1;CL:0000236!1.73e-10!14;CL:0002087!1.44e-09!119;CL:0000738!5.20e-08!140;CL:0002031!3.38e-07!124 | |||
|ontology_enrichment_celltype_v019=CL:0000817;2.70e-40;1!CL:0000785;2.70e-40;1!CL:0000819;2.70e-40;1!CL:0000945;6.13e-27;24!CL:0000236;3.87e-13;13!CL:0000542;7.84e-13;53!CL:0002087;5.67e-09;104 | |||
|ontology_enrichment_celltype_v019_2=CL:0000817,6.39e-53,3;CL:0000819,2.21e-40,1;CL:0000945,5.93e-27,24;CL:0000826,5.93e-27,24;CL:0000785,5.70e-21,2;CL:0000955,5.70e-21,2;CL:0000818,5.70e-21,2;CL:0000954,5.70e-21,2;CL:0000816,5.70e-21,2;CL:0000542,2.83e-19,53;CL:0000051,2.83e-19,53;CL:0000838,7.25e-13,52;CL:0000236,2.82e-12,14;CL:0002087,3.65e-09,115;CL:0000738,7.64e-08,136 | |||
|ontology_enrichment_development_v019=CL:0000954;6.30e-21;2!CL:0000051;7.84e-13;53 | |||
|ontology_enrichment_disease=DOID:12603!6.47e-17!1;DOID:0060073!7.57e-17!1;DOID:8675!7.57e-17!1;DOID:0060058!3.54e-07!10 | |||
|ontology_enrichment_disease_v019=DOID:12603;1.21e-40;1!DOID:0060073;2.70e-40;1!DOID:8675;2.70e-40;1!DOID:0060058;7.21e-17;10!DOID:2531;2.46e-08;51!DOID:0060083;2.46e-08;51 | |||
|ontology_enrichment_disease_v019_2=DOID:12603,1.48e-40,1;DOID:0060073,2.21e-40,1;DOID:8675,2.21e-40,1;DOID:0060058,6.93e-17,10;DOID:2531,4.32e-13,51;DOID:0060083,4.32e-13,51 | |||
|ontology_enrichment_uberon=UBERON:0003127!5.94e-09!2 | |||
|ontology_enrichment_uberon_v019= | |||
|ontology_enrichment_uberon_v019_2= | |||
|phase1_expression=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.0764134057479513,0.164201178899891,0.393553906568396,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2.04383492638291,1.298422916788,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2.58478091468246,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.344743373241465,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.0884575645033392,0,0,0,0,0,0,0,1.64209310294099,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,7.18576330447286,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.0788617450012534,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.115233987555779,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.332660356546013,0,0,0,0,0,0,0,0,0,0 | |||
|short_description=p@chr18:31431849..31431857,+ | |||
}} |
Latest revision as of 00:27, 26 July 2015
Short description: | p@chr18:31431849..31431857, + |
---|---|
Species: | Human (Homo sapiens) |
DPI dataset: | Robust |
TSS-like-by-RIKEN-classifier(Yes/No): | Yes |
DHS support(Yes/No): | Yes |
Description: | CAGE_peak_at_chr18:31431849..31431857, + |
Coexpression cluster: | C78_lymphoma_plasma_tonsil_appendix_lymph_seminal_trachea |
Association with transcript: | NA |
EntrezGene: | NA |
HGNC: | NA |
UniProt: | NA |
Genome view: | ZENBU |
View on UCSC genome browser
CAGE Expression
- Click each plot point to find sample in table
Ontology-based sample term enrichment analysis<b>Summary:</b>This analysis has been performed by utilizing wilcoxon rank sum test.When the number of associated cells/tissues are > n , randomly sampled n cells/tissues are used for P value calculation with rank sum test. this process are repeated several times, and the P values are averaged on the log space <br><b>Analyst:</b> Hideya Kawaji<br><br>link to source dataset<br>data
Ontology term | p-value | n |
---|---|---|
precursor B cell | 6.39e-53 | 3 |
B-1 B cell | 2.21e-40 | 1 |
lymphocyte of B lineage | 5.93e-27 | 24 |
pro-B cell | 5.93e-27 | 24 |
mature B cell | 5.70e-21 | 2 |
pre-B-II cell | 5.70e-21 | 2 |
transitional stage B cell | 5.70e-21 | 2 |
small pre-B-II cell | 5.70e-21 | 2 |
immature B cell | 5.70e-21 | 2 |
lymphocyte | 2.83e-19 | 53 |
common lymphoid progenitor | 2.83e-19 | 53 |
lymphoid lineage restricted progenitor cell | 7.25e-13 | 52 |
B cell | 2.82e-12 | 14 |
nongranular leukocyte | 3.65e-09 | 115 |
leukocyte | 7.64e-08 | 136 |
Ontology term | p-value | n |
---|---|---|
acute leukemia | 1.48e-40 | 1 |
lymphatic system cancer | 2.21e-40 | 1 |
lymphosarcoma | 2.21e-40 | 1 |
lymphoma | 6.93e-17 | 10 |
hematologic cancer | 4.32e-13 | 51 |
immune system cancer | 4.32e-13 | 51 |